Stereoacuity at near · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stereoacuity at distance · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Motor alignment at distance fixation Measured using PACT at 6 months · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Motor fusion test · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Abstinence · cannabis dependence
Selective serotonin reuptake inhibitor antidepressant showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
1 finding from 1 review
Participants with at least some Side Effects · cannabis dependence
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants experiencing adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
1 finding from 1 review